Compare Incyte Corporation (INCY) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Western Union Co — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Western Union Co trades at $6.12 (market cap $1.97B). The key difference: Incyte Corporation is far larger — about 11.6× Western Union Co's market cap, and Western Union Co pays a 14.85% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Western Union Co for 96 Days on average.
| INCY | WU | |
|---|---|---|
Market Cap | $22.85B | $1.97B |
Volume | 1,927,029 | 10,235,212 |
Sector | Health | Financials |
52-Week High | $129.93 | $10.28 |
52-Week Low | $83.80 | $5.90 |
Typical Hold Time | 33 Days | 96 Days |
Enterprise Value | $18.35B | $1.88B |
Dividend Yield | — | 14.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
Western Union (WU) trades at $6.33, up 3.6% today, with mixed technical signals showing a bullish overall trend but bearish moving averages. The stock shows strong profitability with a 43.97% ROE and attractive valuation at 5.1 P/E, though recent earnings misses and declining revenue from $4.5B in 2022 to $4.05B in 2025 raise concerns. The company's $200M efficiency plan and Intermex acquisition aim to revive growth amid competitive pressures.
WU presents a value opportunity with low multiples but faces execution risks from digital disruption and integration challenges. Analyst consensus is cautious with a $6.86 price target and only 12% buy ratings. The stock's upside depends on successful cost savings and regulatory approval of the Intermex deal, while downside risks include further revenue erosion and margin compression.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
